Navigation Links
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Date:6/1/2009

on. Statistically, strong receptor expression correlated with higher pathologic tumor stage and shorter overall survival.

    Conclusion

    - In virtually all patients with prostate cancer, tumor cells appear to
      express LHRH receptors;
    - Even tumors persisting or relapsing after castration or prolonged
      hormonal treatment with LHRH agonists retain the expression of LHRH
      receptors;
    - The continued expression of these receptors supports the concept of
      targeting prostatic LHRH receptors to deliver cytotoxic therapy based
      on LHRH analogs, such as AEZS-108.

A copy of the abstract is currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
2. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
3. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
5. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
6. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
7. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
8. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
11. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... announces the launch of their 2nd generation cell therapy POD® design. The 2nd ... but it also represents a new POD® design. , “G-CON first offered ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ... announces increased partnerships with VA and Military Medical ... Nerve Fiber Density (ENFD) and Sweat Gland Nerve ... fiber neuropathy ( https://therapath.com/skin ). ... Fiber Density (ENFD) on punch skin biopsy is ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3
... ... natural resource use in the 2009 Corporate Sustainability Report. , ... Madison, WI USA (PRWEB) June 22, 2010 ... Sustainability Report . This report summarizes Promega goals and accomplishments to conserve natural resources, ...
... NEW YORK , June 21 Reportlinker.com ... its catalogue: , , ... Molecular Diagnostics Market: DNA Probes and Biochips ... Instrument and Reagent Suppliers , ...
... JUPITER, Fla. , June 21 ... company whose cutting-edge C1 platform technology addresses the needs ... at industrial scale which efficiently convert biomass into ethanol ... it has engaged the influential consulting firm, The Abraham ...
Cached Biology Technology:Promega Releases 2009 Corporate Sustainability Report 2Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 2Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 3Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 4Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 5Reportlinker Adds Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers 6Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... 15, 2010 Scientists at The Scripps Research Institute have ... look for potential drugs targeting a human metabolic enzyme believed ... The new test, which the scientists call a ... thousands of compounds for those that have potential to block ...
... Sept. 15 Fat-derived stem cells can be safely used ... as there is no evidence of active cancer, according to ... findings are available in Tissue Engineering Part A . ... of the body into the breasts for reconstruction, but with ...
... London, UK (September 16, 2010) Amid growing concern ... scrutiny is increasing into the burgeoning DNA sequence trade. ... Atomic Scientists , published by SAGE, looks at the ... the significant barriers to creating one. Synthetic life ...
Cached Biology News:Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 3Fat stem cells safe for breast reconstruction when cancer is dormant, says Pitt team 2Technology to screen for synbio abuses lags 2Technology to screen for synbio abuses lags 3
p21 Ras Immunogen: Recombinant C-H-ras p21(val-12). Storage: 4 C...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
Biology Products: